M&A / Deals Merck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug BioPharma DiveIf consummated, the deal would hand Merck a treatment that could challenge Novartis fast-selling Scemblix.M&A / DealsHematologyRead full story pharminent March 25, 2026 (Last updated: March 25, 2026) BioPharma Dive If consummated, the deal would hand Merck a treatment that could challenge Novartis fast-selling Scemblix. M&A / DealsHematologyRead full story Post navigation Previous: Karyopharm myeloma drug yields mixed data in myelofibrosis trialNext: Sarepta sees early success with RNAi drugs from Arrowhead Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
